Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics, Inc. announced its participation in two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Partners Global Healthcare Conference. Management will provide presentations at both virtual and in-person events in late February and early March 2026. The company is a clinical-stage biotechnology firm focused on developing GeneTAC® gene targeted chimera small molecules for degenerative genetic diseases.
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics, Inc. announced its participation in two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, and the Leerink Partners Global Healthcare Conference on March 10, 2026. The company, a clinical-stage biotechnology firm, will have its management present at these virtual and in-person events to discuss its GeneTAC® gene targeted chimera small molecules platform and its pipeline of therapies for degenerative genetic diseases.
Short Interest in Design Therapeutics, Inc. (NASDAQ:DSGN) Drops By 14.0%
Short interest in Design Therapeutics, Inc. (NASDAQ:DSGN) decreased by 14.0% in January, totaling 1,993,557 shares, representing approximately 4.6% of the company's float. The days-to-cover ratio is 5.6 days based on an average trading volume of 354,260 shares. Analysts generally maintain a "Moderate Buy" consensus rating with a price target of $15.00, and institutional investors own roughly 56.6% of the stock.
Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Design Therapeutics, Inc. (NASDAQ:DSGN) has received a consensus "Moderate Buy" rating from five analysts, with an average one-year price target of $15.00. The company's stock opened at $10.07, and institutional investors currently hold 56.64% of its shares. Design Therapeutics focuses on developing small molecule therapeutic drugs for genetic diseases using its GeneTAC platform.
Design Therapeutics (NASDAQ:DSGN) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen has upgraded Design Therapeutics (NASDAQ:DSGN) from a "sell" to a "hold" rating. The company currently has an average target price of $15.00 and a "Moderate Buy" consensus rating from analysts. Design Therapeutics, a biopharmaceutical company, focuses on developing small molecule therapeutic drugs for genetic diseases, utilizing its GeneTAC platform.
Design Therapeutics announces governance-driven board resignation
Design Therapeutics (DSGN) announced that board member Deepa Prasad will resign effective February 1, 2026, due to conflict-avoidance policies related to her new role at a major bank. The company faces weak financial performance despite a strong balance sheet, with analysts currently rating the stock as a "Hold" with a $10.00 price target. TipRanks' AI Analyst also rates DSGN as "Neutral" due to financial struggles, though technical indicators are supportive.
Design Therapeutics, Inc. Announces Resignation of Deepa Prasad from the Company's Board of Directors, Effective February 1, 2026
Design Therapeutics, Inc. announced that Deepa Prasad will resign from its Board of Directors, effective February 1, 2026. Her resignation is due to conflict-avoidance policies related to a new role she has accepted with a major bank. The company, a biotechnology firm, is involved in developing treatments for genetic diseases such as Friedreich ataxia, Myotonic Dystrophy Type-1, Fuchs Endothelial Corneal Dystrophy, and Huntington's Disease.
Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year High - Here's What Happened
Design Therapeutics (NASDAQ:DSGN) recently hit a new 52-week high of $10.97, closing at $10.59 with significant trading volume. Analyst sentiment for the biopharmaceutical company, which focuses on genetic repeat-expansion diseases, is a "Moderate Buy" with an average price target of $15.00, despite some mixed individual ratings. The company also reported an EPS beat and shows substantial institutional ownership, with firms like RA Capital and JPMorgan increasing their stakes.
Design Therapeutics (NASDAQ:DSGN) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen has downgraded Design Therapeutics (NASDAQ:DSGN) from a "hold" to a "sell" rating. Despite this, the consensus among other analysts remains a "Moderate Buy" with an average price target of $15. The company recently reported better-than-expected EPS and has seen institutional investors like Invesco and Velan Capital increase their holdings, indicating mixed sentiment in the market.
Design Therapeutics (DSGN) Price Target Increased by 10.64% to 13.26
The average one-year price target for Design Therapeutics (NasdaqGS:DSGN) has increased by 10.64% to $13.26 per share, up from $11.98. This new target represents a 38.41% increase from the latest reported closing price of $9.58. Institutional ownership in DSGN shows a bullish outlook, despite a slight decrease in the number of reporting institutions.
Oppenheimer Initiates Coverage of Design Therapeutics (DSGN) with Outperform Recommendation
Oppenheimer has initiated coverage of Design Therapeutics (DSGN) with an Outperform recommendation. The average one-year price target suggests a 35.88% upside from its current share price. The article highlights projected substantial revenue growth and details significant institutional ownership changes and a bullish put/call ratio.
Wall Street Zen Upgrades Design Therapeutics (NASDAQ:DSGN) to "Hold"
Wall Street Zen has upgraded Design Therapeutics (NASDAQ:DSGN) from a "sell" to a "hold" rating, contributing to a "Moderate Buy" consensus among analysts with a $14.00 average target. This upgrade follows several positive shifts from other firms, including RBC, Leerink, and Craig Hallum. DSGN shares opened at $9.10, trade within a 52-week range of $2.60–$10.31, and institutions hold roughly 56.6% of the stock.
Design Therapeutics (NASDAQ:DSGN) Shares Down 4.5% - What's Next?
Design Therapeutics (NASDAQ:DSGN) shares fell 4.5% during mid-day trading with increased volume, closing at $9.35. The company has a "Moderate Buy" consensus rating from analysts with an average target price of $14.00, despite some recent "sell" downgrades. Fundamentals show a market cap of $536.85 million and a negative PE ratio, though Q3 earnings beat estimates.
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Moderate Buy" by Brokerages
Design Therapeutics, Inc. (NASDAQ:DSGN) has received a consensus "Moderate Buy" rating from five brokerage firms, with an average one-year price target of $14.00. Recent analyst activities include upgrades and new coverage, reflecting a generally positive outlook. The biopharmaceutical company, which uses its GeneTAC platform for genetic disease treatments, reported better-than-expected Q3 EPS and has significant institutional investment.
Design Therapeutics Shares Gain Momentum on Clinical Progress
Design Therapeutics' shares rallied by 7.88% to $9.72 following positive clinical and operational developments. The company reported $206.0 million in cash, cash equivalents, and marketable securities as of Q3 2025, and secured regulatory approval to begin clinical development for DT‑818 in Australia. Investors are focused on upcoming clinical milestones, including the initiation of patient dosing in H1 2026 and data readout in 2027, as key drivers for future performance.
Design Therapeutics Advances with New Study on DT-216P2 for Friedreich Ataxia
The provided content is empty, so a summary cannot be generated.
Design Therapeutics (NASDAQ:DSGN) Sees Strong Trading Volume - Should You Buy?
Design Therapeutics (NASDAQ:DSGN) experienced a significant surge in trading volume, with approximately 618,642 shares traded, a 237% increase from the prior session. The company holds a "Moderate Buy" consensus rating from analysts with an average price target of $14. Institutional investors hold about 56.6% of the stock, and the company recently beat its quarterly EPS estimates.
Design Therapeutics (NASDAQ:DSGN) Shares Down 4.5% - Should You Sell?
Shares of Design Therapeutics (NASDAQ:DSGN) dropped 4.5% during mid-day trading on Wednesday, closing at $9.19 with a significantly lower trading volume than average. Despite the stock's downturn, analyst sentiment remains mixed but leans positive, with several firms upgrading their ratings and setting an average price target of $14. The company, which has a market cap of $531 million, reported a quarterly EPS beat and institutional investors currently own over 56% of its stock.
Design Therapeutics (DSGN) details 295,312 performance option shares vested
Design Therapeutics reported that its President, CEO, and Chairperson, Pratik Shah, had 295,312 stock option shares vest on December 9, 2025, after a specific performance condition was met. This vesting is part of a larger stock option for 525,000 shares granted on September 1, 2023, with an exercise price of $2.48 per share. The remaining unvested shares will continue to vest in monthly installments through August 25, 2027, contingent on his continued service to the company.
Design Therapeutics (DSGN) Price Target Increased by 41.00% to 11.98
The average one-year price target for Design Therapeutics (NasdaqGS:DSGN) has increased by 41.00% to $11.98 per share from the prior estimate of $8.50. This new target represents a 22.67% increase from the last reported closing price. Institutional holdings in DSGN show varying activities, with some increasing and others decreasing their positions.
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress
Leerink Partners upgraded Design Therapeutics (NASDAQ:DSGN) to Outperform and doubled its price target to $14.00, citing progress with its reformulated Friedreich’s Ataxia treatment candidate, DT-216P2, and its new myotonic dystrophy type 1 candidate, DT-818. This upgrade follows RBC Capital's similar move, highlighting the company's successful pivot in its development strategy. Design Therapeutics is advancing multiple programs, with clinical data and trials expected in 2026 and 2027.
Design Therapeutics (NASDAQ:DSGN) Coverage Initiated by Analysts at Craig Hallum
Craig Hallum has initiated coverage on Design Therapeutics (NASDAQ:DSGN) with a "buy" rating, contributing to a consensus "Buy" rating and a target price of $14.00 among analysts. The stock opened at $9.82, near its 52-week high, with a market capitalization of $559.4 million. Despite a negative expected EPS for the fiscal year, institutional investors hold a significant 56.64% of the company's stock.
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages
Design Therapeutics, Inc. (NASDAQ:DSGN) has received a "Moderate Buy" consensus rating from five analysts, with an average 12-month price target of $14.00. Institutional investors own 56.64% of the stock, and the company recently reported Q3 EPS of ($0.30), exceeding estimates. Shares opened at $9.77, trading near its 12-month high.
Reinforcement Learning Methods for Generating Optimal Investment Strategies in Stock Markets
Craig-Hallum initiated coverage on Design Therapeutics Inc. (NASDAQ:DSGN) with a "Buy" rating and a $15.00 price target, citing the company's "underappreciated GeneTAC platform" and potential catalysts in H2 2026. Design Therapeutics has shown strong year-to-date performance, outperforming the XBI, and holds more cash than debt. The firm anticipates upcoming clinical readouts for Friedreich’s ataxia and Fuchs disease to significantly de-risk the company's genetic medicine story and improve market perception.
Craig-Hallum initiates Design Therapeutics stock with Buy rating By Investing.com
Craig-Hallum has initiated coverage on Design Therapeutics Inc (NASDAQ:DSGN) with a Buy rating and a $15.00 price target, citing the company's "underappreciated GeneTAC platform" and potential catalysts in the second half of 2026. The company also recently received upgrades from Leerink Partners and RBC Capital due to progress with potential treatments for Friedreich's Ataxia and myotonic dystrophy type-1. Design Therapeutics' stock has risen 45% year-to-date and holds more cash than debt, with upcoming clinical readouts expected to transform market perception.
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress
Leerink Partners has upgraded Design Therapeutics (NASDAQ:DSGN) to Outperform, doubling its price target to $14 from $7, citing pipeline progress with its Friedreich’s Ataxia treatment candidate, DT-216P2, and its new DM1 candidate, DT-818. This upgrade follows improved pharmacokinetics for DT-216P2 and positive prospects for DT-818 as a potential best-in-class treatment. The company has also secured ex-US regulatory clearance for DT-818, with a Phase 1 trial expected in Australia in early 2026.
Leerink Upgrades Design Therapeutics to Outperform From Market Perform, Adjusts PT to $14 From $7
Leerink has upgraded Design Therapeutics (DSGN) to "Outperform" from "Market Perform" and raised its price target to $14 from $7. This upgrade reflects confidence in the company's prospects. The article also mentions recent news and analyst actions, including RBC's upgrade and price target boost.
Design Therapeutics stock rating upgraded by RBC Capital on improved outlook
RBC Capital has upgraded Design Therapeutics (NASDAQ:DSGN) from Sector Perform to Outperform, more than doubling its price target to $13.00 due to an improved outlook and potential for "clinically meaningful benefits" from its lead Friedreich's ataxia program. The firm anticipates an "eventful 2026," with additional upside from other programs and projected revenues exceeding $1.9 billion by 2034. This upgrade follows recent regulatory clearance for DT-818 outside the U.S. and plans for a Phase 1 trial in Australia in early 2026.
Design Therapeutics (Nasdaq: DSGN) to Participate in Piper Sandler and Evercore 2025 Events
Design Therapeutics (Nasdaq: DSGN) announced its management will participate in two upcoming investor fireside chats in early December 2025. These include the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and the Evercore 8th Annual Healthcare Conference on December 4, 2025. Live webcasts of both presentations will be available on the company’s investor relations website and archived for at least 30 days.
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company, announced its management will participate in two upcoming investor conferences: the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and the Evercore 8th Annual Healthcare Conference on December 4, 2025. Live webcasts of these fireside chats will be available on the company's website. The company is focused on developing GeneTAC® gene targeted chimera small molecules to treat serious degenerative genetic diseases.
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics, Inc. (Nasdaq: DSGN) announced its management will participate in fireside chats at two upcoming investor conferences: the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and the Evercore 8th Annual Healthcare Conference on December 4, 2025. The company, a clinical-stage biotechnology firm, specializes in developing treatments for serious degenerative genetic diseases using its GeneTAC® gene targeted chimera small molecules platform. Webcasts of these presentations will be available on the company's website.
Los Angeles Daily News - Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics, Inc. (Nasdaq: DSGN) announced its participation in two upcoming investor conferences: the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and the Evercore 8th Annual Healthcare Conference on December 4, 2025. Management will present at fireside chats during these events. The clinical-stage biotechnology company focuses on developing treatments for serious degenerative genetic diseases using its GeneTAC® gene targeted chimera small molecules platform.
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Design Therapeutics (NASDAQ:DSGN), a company that generates no revenue, holds US$206m in cash and is debt-free as of September 2025. With a current cash burn rate of US$52m annually, the company boasts a cash runway of 3.9 years, providing ample time for business development despite a 13% increase in its cash burn over the last year. Its cash burn represents only 11% of its US$476m market capitalization, suggesting it could raise additional funds without significant dilution.
Design (NASDAQ: DSGN) gains ex-US regulatory clearance; DT-818 dosing DM1 H1 2026
Design Therapeutics (NASDAQ: DSGN) announced the nomination of DT-818 as its development candidate for myotonic dystrophy type-1 (DM1) and received ex-US regulatory clearance for clinical development. The company plans to initiate patient dosing in a Phase 1 trial in Australia in the first half of 2026, with splicing data expected in 2027. Design is also progressing trials for DT-216P2 and DT-168, with data anticipated in the second half of 2026, and reported a strong cash position of $206.0 million as of Q3 2025.
Design Therapeutics unveils DT-818 for myotonic dystrophy treatment
Design Therapeutics (NASDAQ:DSGN) has received ex-US regulatory clearance for its GeneTAC small molecule, DT-818, for the treatment of myotonic dystrophy type-1 (DM1). The company plans to begin Phase 1 dosing in Australia in early 2026, anticipating promising preclinical results to translate into clinical success. Design Therapeutics also provided updates on other clinical programs and reported a Q3 2025 net loss of $17.0 million, maintaining a strong financial position with $206.0 million in cash.
Design Therapeutics Advances DT-168 Study for Fuchs Dystrophy
Design Therapeutics, Inc. announced an update on its Phase 2 clinical study for DT-168 ophthalmic solution, aimed at treating Fuchs endothelial corneal dystrophy in patients undergoing keratoplasty. The study, which began on May 20, 2025, is evaluating the pharmacodynamics, safety, and tolerability of DT-168. Positive results could significantly impact the company's stock and the broader ophthalmic treatment market.
Design Therapeutics Appoints Justin Gover to Board of Directors
Design Therapeutics, a clinical-stage biotechnology company, announced the appointment of Justin Gover to its Board of Directors. Gover, former CEO of GW Pharmaceuticals, brings over 25 years of leadership experience and will provide strategic guidance as the company advances its clinical pipeline. Dr. Arsani William stepped down from the board, with Design Therapeutics acknowledging his instrumental contributions since 2021.
Design Therapeutics, Inc. Reports Initial Safety Data for DT-216P2 in Friedreich Ataxia Trial Amid FDA Clinical Hold on U.S. IND Application
Design Therapeutics, Inc. announced initial safety data for its drug DT-216P2 in a Friedreich ataxia trial, showing favorable safety and pharmacokinetics with no adverse events. Concurrently, the FDA issued a clinical hold on the company's IND application for U.S. trial sites due to nonclinical deficiencies. The company plans to address the FDA's concerns while continuing patient enrollment in Australia, with data from the multi-ascending dose trial expected in 2026.
Design Therapeutics Achieves First Patient Dosing in Friedreich Ataxia Trial, Faces FDA Hurdle
Design Therapeutics has begun dosing its first Friedreich ataxia patient in the RESTORE-FA Phase 1/2 trial in Australia, showing favorable safety and improved drug exposure with its DT-216P2 formulation. Despite this clinical progress, the company faces a significant hurdle as the FDA has placed a clinical hold on its IND application for U.S. trial sites due to nonclinical deficiencies, delaying expansion within the U.S. Data from the multiple-ascending dose trial, including frataxin expression levels, is expected in 2026.
Los Angeles Daily News - Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
Design Therapeutics, Inc. (Nasdaq: DSGN) announced its management will participate in a fireside chat at the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York. A live webcast will be available via their website. The company is a clinical-stage biotechnology firm focused on developing therapies for degenerative genetic diseases using its GeneTAC® platform.
Design Therapeutics To Initiate Phase 2 Biomarker Trial Of DT-168 In FECD In 2H 2025
Design Therapeutics Inc. announced positive Phase 1 trial results for DT-168, an eye drop treatment for Fuchs endothelial corneal dystrophy (FECD). DT-168, a first-in-class GeneTAC small molecule therapy, was well-tolerated and showed no serious adverse events. The company plans to initiate a Phase 2 biomarker trial in the second half of 2025 to evaluate the treatment's activity in FECD patients.
First Clinical Trial of GeneTAC Therapy for FA Expected in 2022
Design Therapeutics is on track to launch the first clinical trial for its GeneTAC therapy for Friedreich's ataxia (FA) in the first half of 2022, with top-line results anticipated in the second half of next year. The therapy, a new class of small molecules, aims to address the underlying cause of FA by promoting the production of full-length frataxin mRNA. Preclinical studies have shown promising results, with the FA GeneTAC molecule leading to sustained increases in frataxin levels approaching those of healthy individuals.
